Published in Endocrinology on December 13, 2011
To Determine Tolerability to Glucagon Infusion in Obese Subjects (GIO) | NCT02817659
Effects of Glucagon Administration on Energy Expenditure (GLEE) | NCT02237053
Glucagon Response to Prandial Insulin Administration in Persons With Type 1 Diabetes | NCT04079881
Coadministration of glucagon-like peptide-1 during glucagon infusion in humans results in increased energy expenditure and amelioration of hyperglycemia. Diabetes (2012) 1.13
Avoiding hypoglycemia: a key to success for glucose-lowering therapy in type 2 diabetes. Vasc Health Risk Manag (2013) 1.09
Minireview: The role of the autonomic nervous system in mediating the glucagon response to hypoglycemia. Endocrinology (2012) 1.08
Retinoic acid-related orphan receptors α and γ: key regulators of lipid/glucose metabolism, inflammation, and insulin sensitivity. Front Endocrinol (Lausanne) (2013) 1.06
Defective counterregulation and hypoglycemia unawareness in diabetes: mechanisms and emerging treatments. Endocrinol Metab Clin North Am (2012) 0.93
Lack of association between residual insulin production and glucagon response to hypoglycemia in youth with short duration of type 1 diabetes. Diabetes Care (2013) 0.91
Coming of age: the artificial pancreas for type 1 diabetes. Diabetologia (2016) 0.90
Pathway-selective insulin resistance and metabolic disease: the importance of nutrient flux. J Biol Chem (2014) 0.86
Ghrelin: much more than a hunger hormone. Curr Opin Clin Nutr Metab Care (2013) 0.85
Minimizing morbidity of hypoglycemia in diabetes: a review of mini-dose glucagon. J Diabetes Sci Technol (2014) 0.84
Quantification of the glycemic response to microdoses of subcutaneous glucagon at varying insulin levels. Diabetes Care (2014) 0.83
Blunted glucagon but not epinephrine responses to hypoglycemia occurs in youth with less than 1 yr duration of type 1 diabetes mellitus. Pediatr Diabetes (2013) 0.83
A computational systems analysis of factors regulating α cell glucagon secretion. Islets (2012) 0.82
Somatostatin receptor type 2 antagonism improves glucagon counterregulation in biobreeding diabetic rats. Diabetes (2013) 0.81
Pancreatic α-Cell Dysfunction in Type 2 Diabetes: Old Kids on the Block. Diabetes Metab J (2015) 0.81
Biochemical stabilization of glucagon at alkaline pH. Diabetes Technol Ther (2014) 0.80
SUMO1 enhances cAMP-dependent exocytosis and glucagon secretion from pancreatic α-cells. J Physiol (2014) 0.80
Glucose control of glucagon secretion-'There's a brand-new gimmick every year'. Ups J Med Sci (2016) 0.80
Resting metabolic rate in obese diabetic and obese non-diabetic subjects and its relation to glycaemic control. BMC Res Notes (2013) 0.79
Neuronostatin acts via GPR107 to increase cAMP-independent PKA phosphorylation and proglucagon mRNA accumulation in pancreatic α-cells. Am J Physiol Regul Integr Comp Physiol (2015) 0.79
Effect of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) on hormones of energy balance in a TCDD-sensitive and a TCDD-resistant rat strain. Int J Mol Sci (2014) 0.79
Current insights and new perspectives on the roles of hyperglucagonemia in non-insulin-dependent type 2 diabetes. Curr Hypertens Rep (2013) 0.79
The p75 neurotrophin receptor is required for the major loss of sympathetic nerves from islets under autoimmune attack. Diabetes (2014) 0.79
The Identification of Novel Protein-Protein Interactions in Liver that Affect Glucagon Receptor Activity. PLoS One (2015) 0.78
Posttranscriptional regulation of adrenal TH gene expression contributes to the maladaptive responses triggered by insulin-induced recurrent hypoglycemia. Physiol Rep (2015) 0.77
Obesity: Current and potential pharmacotherapeutics and targets. Pharmacol Ther (2016) 0.75
Short-term diabetic hyperglycemia suppresses celiac ganglia neurotransmission, thereby impairing sympathetically mediated glucagon responses. Am J Physiol Endocrinol Metab (2015) 0.75
Growth Hormone-Releasing Hormone in Diabetes. Front Endocrinol (Lausanne) (2016) 0.75
Adrenaline: insights into its metabolic roles in hypoglycaemia and diabetes. Br J Pharmacol (2016) 0.75
Oxyntomodulin increases intrinsic heart rate through the glucagon receptor. Physiol Rep (2013) 0.75
Clinical utility and patient considerations in the use of the sitagliptin-metformin combination in Chinese patients. Patient Prefer Adherence (2015) 0.75
Preventive effect of ipragliflozin on nocturnal hypoglycemia in patients with type 2 diabetes treated with basal-bolus insulin therapy: An open-label, single-center, parallel, randomized control study. J Diabetes Investig (2016) 0.75
The search for the mechanism of early sympathetic islet neuropathy in autoimmune diabetes. Diabetes Obes Metab (2014) 0.75
Dipeptidyl peptidase-4 inhibitor (vildagliptin) improves glycemic control after meal tolerance test by suppressing glucagon release. Drugs R D (2014) 0.75
The effects of voluntary exercise and prazosin on capillary rarefaction and metabolism in streptozotocin-induced diabetic male rats. J Appl Physiol (1985) (2016) 0.75
Glucoregulatory, endocrine and morphological effects of [P5K]hymenochirin-1B in mice with diet-induced glucose intolerance and insulin resistance. Naunyn Schmiedebergs Arch Pharmacol (2016) 0.75
The physiology of glucagon-like peptide 1. Physiol Rev (2007) 9.07
Regulation of hepatic fatty acid oxidation and ketone body production. Annu Rev Biochem (1980) 7.03
The unique cytoarchitecture of human pancreatic islets has implications for islet cell function. Proc Natl Acad Sci U S A (2006) 5.41
Studies of pancreatic alpha cell function in normal and diabetic subjects. J Clin Invest (1970) 4.74
Alpha-cells of the endocrine pancreas: 35 years of research but the enigma remains. Endocr Rev (2007) 3.86
Lower blood glucose, hyperglucagonemia, and pancreatic alpha cell hyperplasia in glucagon receptor knockout mice. Proc Natl Acad Sci U S A (2003) 3.53
Abnormal alpha-cell function in diabetes. Response to carbohydrate and protein ingestion. N Engl J Med (1970) 3.27
Leptin therapy in insulin-deficient type I diabetes. Proc Natl Acad Sci U S A (2010) 3.23
Insulin signaling in alpha cells modulates glucagon secretion in vivo. Cell Metab (2009) 2.83
Insulin within islets is a physiologic glucagon release inhibitor. J Clin Invest (1984) 2.52
The role of alpha-cell dysregulation in fasting and postprandial hyperglycemia in type 2 diabetes and therapeutic implications. Endocr Rev (2007) 2.51
Mechanism of awareness of hypoglycemia. Perception of neurogenic (predominantly cholinergic) rather than neuroglycopenic symptoms. Diabetes (1993) 2.37
Hypoglycemia-associated autonomic failure in insulin-dependent diabetes mellitus. Recent antecedent hypoglycemia reduces autonomic responses to, symptoms of, and defense against subsequent hypoglycemia. J Clin Invest (1993) 2.35
Lack of suppression of glucagon contributes to postprandial hyperglycemia in subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab (2000) 2.15
Glucagon receptor knockout prevents insulin-deficient type 1 diabetes in mice. Diabetes (2011) 2.08
Beta-cell secretory products activate alpha-cell ATP-dependent potassium channels to inhibit glucagon release. Diabetes (2005) 2.04
Glutamate is a positive autocrine signal for glucagon release. Cell Metab (2008) 2.01
Documentation of hyperglucagonemia throughout the day in nonobese and obese patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab (1987) 1.96
Hepatic and glucagon-like peptide-1-mediated reversal of diabetes by glucagon receptor antisense oligonucleotide inhibitors. J Clin Invest (2004) 1.93
Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance. N Engl J Med (1992) 1.82
Prevention of human diabetic ketoacidosis by somatostatin. Evidence for an essential role of glucagon. N Engl J Med (1975) 1.80
Paracrinology of islets and the paracrinopathy of diabetes. Proc Natl Acad Sci U S A (2010) 1.79
Intra-islet insulin suppresses glucagon release via GABA-GABAA receptor system. Cell Metab (2006) 1.76
Hypoglycemia-associated autonomic failure in advanced type 2 diabetes. Diabetes (2002) 1.75
Brain glucose sensing, counterregulation, and energy homeostasis. Physiology (Bethesda) (2007) 1.74
Meal-stimulated glucagon release is associated with postprandial blood glucose level and does not interfere with glycemic control in children and adolescents with new-onset type 1 diabetes. J Clin Endocrinol Metab (2007) 1.72
Reduction in glucagon receptor expression by an antisense oligonucleotide ameliorates diabetic syndrome in db/db mice. Diabetes (2004) 1.65
The role of adrenergic mechanisms in the substrate and hormonal response to insulin-induced hypoglycemia in man. J Clin Invest (1976) 1.63
Characterization of the effects of arginine and glucose on glucagon and insulin release from the perfused rat pancreas. J Clin Invest (1974) 1.55
Pathogenesis of fasting and postprandial hyperglycemia in type 2 diabetes: implications for therapy. Diabetes (2010) 1.53
Hormonal mechanisms of recovery from insulin-induced hypoglycemia in man. Am J Physiol (1979) 1.53
Intraislet hyperinsulinemia prevents the glucagon response to hypoglycemia despite an intact autonomic response. Diabetes (2002) 1.49
Somatostatin release, electrical activity, membrane currents and exocytosis in human pancreatic delta cells. Diabetologia (2009) 1.46
Glycemic control in mice with targeted disruption of the glucagon receptor gene. Biochem Biophys Res Commun (2002) 1.44
Impact of lack of suppression of glucagon on glucose tolerance in humans. Am J Physiol (1999) 1.44
Role of brain in counterregulation of insulin-induced hypoglycemia in dogs. Diabetes (1989) 1.42
Zinc, not insulin, regulates the rat alpha-cell response to hypoglycemia in vivo. Diabetes (2007) 1.39
Effects of a novel glucagon receptor antagonist (Bay 27-9955) on glucagon-stimulated glucose production in humans. Diabetologia (2001) 1.38
Correlation between minimal secretory capacity of pancreatic beta-cells and stability of diabetic control. Diabetes (1988) 1.37
Too much glucagon, too little insulin: time course of pancreatic islet dysfunction in new-onset type 1 diabetes. Diabetes Care (2008) 1.36
Glucose homeostasis during prolonged suppression of glucagon and insulin secretion by somatostatin. Proc Natl Acad Sci U S A (1977) 1.35
Contribution of abnormal muscle and liver glucose metabolism to postprandial hyperglycemia in NIDDM. Diabetes (1990) 1.33
Physiologic action of glucagon on liver glucose metabolism. Diabetes Obes Metab (2011) 1.32
Role of hyperglucagonemia in maintenance of increased rates of hepatic glucose output in type II diabetics. Diabetes (1987) 1.27
Insulin as a physiological modulator of glucagon secretion. Am J Physiol Endocrinol Metab (2008) 1.26
Glucagon, catecholamine and pancreatic polypeptide secretion in type I diabetic recipients of pancreas allografts. J Clin Invest (1990) 1.26
Autonomic mediation of glucagon secretion during hypoglycemia: implications for impaired alpha-cell responses in type 1 diabetes. Diabetes (1998) 1.25
Homozygous P86S mutation of the human glucagon receptor is associated with hyperglucagonemia, alpha cell hyperplasia, and islet cell tumor. Pancreas (2009) 1.22
Regulation of glucagon secretion by glucose: paracrine, intrinsic or both? Diabetes Obes Metab (2011) 1.21
Evidence for an important role of glucagon in the regulation of hepatic glucose production in normal man. J Clin Invest (1977) 1.19
Glucagon deficiency reduces hepatic glucose production and improves glucose tolerance in adult mice. Mol Endocrinol (2010) 1.19
Glucagon receptor antagonism improves islet function in mice with insulin resistance induced by a high-fat diet. Diabetologia (2007) 1.17
Postprandial suppression of glucagon secretion depends on intact pulsatile insulin secretion: further evidence for the intraislet insulin hypothesis. Diabetes (2006) 1.16
Evidence for a major role for glucagon in regulation of plasma glucose in conscious, nondiabetic, and alloxan-induced diabetic rabbits. Diabetes (1996) 1.16
Mechanisms for abnormal postprandial glucose metabolism in type 2 diabetes. Am J Physiol Endocrinol Metab (2005) 1.16
Benefits and limitations of reducing glucagon action for the treatment of type 2 diabetes. Am J Physiol Endocrinol Metab (2008) 1.15
Insulin reciprocally regulates glucagon secretion in humans. Diabetes (2010) 1.15
Glucose-regulated glucagon secretion requires insulin receptor expression in pancreatic alpha-cells. J Biol Chem (2005) 1.14
Efficacy of metreleptin in obese patients with type 2 diabetes: cellular and molecular pathways underlying leptin tolerance. Diabetes (2011) 1.10
Failure of glucagon suppression contributes to postprandial hyperglycaemia in IDDM. Diabetologia (1995) 1.09
Loss of inverse relationship between pulsatile insulin and glucagon secretion in patients with type 2 diabetes. Diabetes (2011) 1.07
Recombinant human leptin treatment does not improve insulin action in obese subjects with type 2 diabetes. Diabetes (2011) 1.03
The vascular order of islet cellular perfusion in the human pancreas. Diabetes (1992) 1.02
Role of the decrement in intraislet insulin for the glucagon response to hypoglycemia in humans. Diabetes Care (2005) 1.01
Effects of insulin per se on neuroendocrine and metabolic counter-regulatory responses to hypoglycaemia. Clin Sci (Lond) (2000) 1.00
A novel glucagon receptor antagonist, NNC 25-0926, blunts hepatic glucose production in the conscious dog. J Pharmacol Exp Ther (2007) 1.00
Immunoneutralization of somatostatin, insulin, and glucagon causes alterations in islet cell secretion in the isolated perfused human pancreas. Pancreas (2001) 1.00
Activation of autonomic nerves and the adrenal medulla contributes to increased glucagon secretion during moderate insulin-induced hypoglycemia in women. Diabetes (1997) 0.98
Glucagon response to hypoglycemia in sympathectomized man. J Clin Invest (1976) 0.98
Nesidioblastosis and hyperplasia of alpha cells, microglucagonoma, and nonfunctioning islet cell tumor of the pancreas: review of the literature. Pancreas (2008) 0.98
The effect of pegylated recombinant human leptin (PEG-OB) on weight loss and inflammatory status in obese subjects. Int J Obes Relat Metab Disord (2002) 0.97
Effect of three treatment schedules of recombinant methionyl human leptin on body weight in obese adults: a randomized, placebo-controlled trial. Diabetes Obes Metab (2005) 0.95
Discovery of potent, orally active benzimidazole glucagon receptor antagonists. Bioorg Med Chem Lett (2008) 0.94
Effect of insulin therapy on the profiles of plasma immunoreactive glucagon in juvenile-type and adult-type diabetics. Diabetes (1978) 0.94
Increasing the decrement in insulin secretion improves glucagon responses to hypoglycemia in advanced type 2 diabetes. Diabetes Care (2005) 0.94
Beta-cell-mediated signaling predominates over direct alpha-cell signaling in the regulation of glucagon secretion in humans. Diabetes Care (2009) 0.93
Action of glucagon and glucagon-like peptide-1-(7-36) amide on lipolysis in human subcutaneous adipose tissue and skeletal muscle in vivo. J Clin Endocrinol Metab (2001) 0.92
Glucagon's actions are modified by the combination of epinephrine and gluconeogenic precursor infusion. Am J Physiol Endocrinol Metab (2003) 0.88
Leptin downregulates expression of the gene encoding glucagon in alphaTC1-9 cells and mouse islets. Diabetologia (2011) 0.86
Fasting hyperglycemia impairs glucose- but not insulin-mediated suppression of glucagon secretion. J Clin Endocrinol Metab (2007) 0.85
Beta- and alpha-cell dysfunction in subjects developing impaired glucose tolerance: outcome of a 12-year prospective study in postmenopausal Caucasian women. Diabetes (2008) 0.84
Physiological levels of glucagon do not influence lipolysis in abdominal adipose tissue as assessed by microdialysis. J Clin Endocrinol Metab (2001) 0.84
Epinephrine supports the postabsorptive plasma glucose concentration and prevents hypoglycemia when glucagon secretion is deficient in man. J Clin Invest (1984) 0.84
Pancreatic response to mild non-insulin-induced hypoglycemia does not involve extrinsic neural input. Diabetes (2001) 0.82
The effects of SMS 201-995 (sandostatin) on metabolic profiles in insulin-dependent diabetes mellitus. J Clin Endocrinol Metab (1989) 0.82
Long-term hyperglucagonaemia induces early metabolic and renal phenotypes of Type 2 diabetes in mice. Clin Sci (Lond) (2008) 0.82
First proof of pharmacology in humans of a novel glucagon receptor antisense drug. J Clin Pharmacol (2014) 0.81
Combination of continuous subcutaneous infusion of insulin and octreotide in Type 1 diabetic patients. Diabetes Res Clin Pract (2001) 0.81
Metabolic effects of long-acting somatostatin analogue (sandostatin) in type I diabetic patients on conventional therapy. Diabetes (1989) 0.81
Effects of acute hyperglucagonemia on hepatic and intestinal lipoprotein production and clearance in healthy humans. Diabetes (2010) 0.81
Pharmacokinetic and pharmacodynamic modeling of a monoclonal antibody antagonist of glucagon receptor in male ob/ob mice. AAPS J (2009) 0.80
Glucagon, in concert with insulin, supports the postabsorptive plasma glucose concentration in humans. Diabetes (2007) 0.80
Native pancreatic alpha-cell adaptation in streptozotocin-induced diabetic primates: importance for pig islet xenotransplantation. Xenotransplantation (2009) 0.79
Basal insulin, glucagon, and growth hormone replacement. Am J Physiol Endocrinol Metab (2007) 0.79
Hyperglycemia induced by somatostatin in normal subjects. Horm Metab Res (1976) 0.79
Does glucagon have a lipolytic effect? Clin Endocrinol (Oxf) (2001) 0.78
Autonomic neural control mechanisms of substrate and hormonal responses to acute hypoglycaemia in man. Clin Endocrinol (Oxf) (1981) 0.78
Effects of the somatostatin analog, octreotide, on glucose metabolism and insulin sensitivity in insulin-dependent diabetes mellitus. Metabolism (1996) 0.78